PRIMA Trial Dosing
Lower Rates of Select Hematologic Adverse Reactions Were Observed With an Individualized Starting Dose1
PRIMA prospectively evaluated the safety and efficacy of an individualized starting dose of either 200 mg or 300 mg, selected based on baseline weight and platelet count, as well as a fixed starting dose of 300 mg.1
In PRIMA, patients in the overall and individualized populations experienced the same rates of Grades 3-4 leukopenia.
The Safety and Tolerability Profile Is Well Characterized and Consistent With Previous Clinical Trial Experience1,3
Side effects of ZEJULA may be managed with dose interruption and modification1,3
- Adverse events led to dose interruptions or reduction in 80% of patients, most frequently from thrombocytopenia (56%), anemia (33%), and neutropenia (20%)
- No specific drug-drug interactions have been reported with ZEJULA*